The estimated Net Worth of Jacqueline Elizabeth Shea is at least $2.24 Million dollars as of 15 May 2024. Jacqueline Shea owns over 17,745 units of Inovio Pharmaceuticals Inc stock worth over $270,941 and over the last 6 years he sold INO stock worth over $812,192. In addition, he makes $1,157,030 as Chief Operating Officer at Inovio Pharmaceuticals Inc.
Jacqueline has made over 15 trades of the Inovio Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 17,745 units of INO stock worth $116,230 on 15 May 2024.
The largest trade he's ever made was exercising 92,778 units of Inovio Pharmaceuticals Inc stock on 26 February 2023 worth over $607,696. On average, Jacqueline trades about 29,300 units every 76 days since 2019. As of 15 May 2024 he still owns at least 41,365 units of Inovio Pharmaceuticals Inc stock.
You can see the complete history of Jacqueline Shea stock trades at the bottom of the page.
Dr. Jacqueline Elizabeth Elizabeth Shea Ph.D. serves as Chief Operating Officer of the Company. Dr. Shea has served as our Chief Operating Officer since March 2019. Prior to joining us, Dr. Shea served as chief executive officer of Aeras, a nonprofit organization developing tuberculosis vaccines, from August 2015 to December 2018, and as its chief operating officer from April 2014 to August 2015. Dr. Shea previously served as Vice President of Business Development, Europe for Emergent BioSolutions Inc. from May 2013 to March 2014, having previously served as Senior Director of Business Development for Emergent BioSolutions from 2005 to 2008. She was general manager of The Oxford-Emergent Tuberculosis Consortium, a global health joint venture formed between Oxford University and Emergent BioSolutions, from 2008 to 2013. She started her career as a post-doctoral researcher at Imperial College, London. Dr. Shea holds a Ph.D. from the National Institute for Medical Research and a B.S. in applied biology from University of Bath.
As the Chief Operating Officer of Inovio Pharmaceuticals Inc, the total compensation of Jacqueline Shea at Inovio Pharmaceuticals Inc is $1,157,030. There are 2 executives at Inovio Pharmaceuticals Inc getting paid more, with Jong Kim having the highest compensation of $2,588,530.
Jacqueline Shea is 55, he's been the Chief Operating Officer of Inovio Pharmaceuticals Inc since 2019. There are 8 older and 6 younger executives at Inovio Pharmaceuticals Inc. The oldest executive at Inovio Pharmaceuticals Inc is Simon Benito, 75, who is the Independent Chairman of the Board.
Jacqueline's mailing address filed with the SEC is 660 W. GERMANTOWN PIKE, , PLYMOUTH MEETING, PA, 19462.
Over the last 19 years, insiders at Inovio Pharmaceuticals Inc have traded over $23,656,819 worth of Inovio Pharmaceuticals Inc stock and bought 1,958,377 units worth $5,174,071 . The most active insiders traders include Austin W & Greenhouse David..., Jong Joseph Kim und Felix Theeuwes. On average, Inovio Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $745,390. The most recent stock trade was executed by Michael John Sumner on 30 June 2024, trading 2,917 units of INO stock currently worth $19,106.
inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.
Inovio Pharmaceuticals Inc executives and other stock owners filed with the SEC include: